BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Venglustat (GZ/SAR402671) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Venglustat (GZ/SAR402671)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07927140-1714@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20300114
DTEND;VALUE=DATE:20300115
SUMMARY:Venglustat (GZ/SAR402671): Phase 3 readout est. (NCT07927140)
DESCRIPTION:Venglustat (GZ/SAR402671)\, phase 3\, Gaucher Disease.\nStudy: 
 The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric 
 Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)\nEstim
 ated primary completion: 14 January 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/venglustat-gz-sar402671#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07927140
URL:https://assetmemo.bio/drug/venglustat-gz-sar402671#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
